Premature Ovarian Insufficiency and Platelet-rich plasma (PRP): what the trial registry contains

Why this is studied in Premature Ovarian Insufficiency

Primary ovarian insufficiency is loss of ovarian function before forty, from genetic, autoimmune or iatrogenic causes. Cell and platelet-based 'ovarian rejuvenation' aims to restore folliculogenesis. Occasional spontaneous ovulation occurs in this condition — including spontaneous pregnancies — which is the fact most often exploited by uncontrolled case reports.

What PRP means in this table

Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.

The numbers

Every figure below comes from one reproducible query (primary ovarian insufficiency x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Evidence here is mid-maturity: a handful of Phase 3 or 4 registrations (2 of 17) sit above a much larger early-phase base.

Registrations do not all survive contact with recruitment — 6 completed here, 0 stopped early, giving a 0% attrition rate.

Median planned enrolment is 100 participants (largest single study: 500). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

12 countries host at least one site. United States is the largest single contributor at roughly 25% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Funding profile: 3 academic or hospital sponsors against 4 commercial ones — commercial overall, which is worth knowing before reading any single positive report.

• Peking University Third Hospital — 2 records
• Reproductive Medicine Associates of New Jersey — 1 record
• Forever Young d.o.o. — 1 record
• Genesis Athens Clinic — 1 record
• Center for Human Reproduction — 1 record
• The Fourth Affiliated Hospital of Zhejiang University School of Medicine — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

Registration counts measure activity, not effect. A study appears here the moment it is registered — before any participant is enrolled, and regardless of whether results are ever posted.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many PRP studies for Premature Ovarian Insufficiency are recruiting right now?

2 of 17 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is PRP an approved treatment for Premature Ovarian Insufficiency?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 17 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on PRP for Premature Ovarian Insufficiency?

2 of 17 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2012 to 2025.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.